ASTIN and PROLASTIN-C are made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and, theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, and cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products. Individuals with selective IgA deficiencies who have the known antibody against IgA (anti-IgA antibody) should not receive PROLASTIN or PROLASTIN-C, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present. For additional information on PROLASTIN, please see full prescribing information at www.PROLASTIN.com
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
About Alpha1-Antitrypsin Deficiency
Alpha1-antitrypsin deficiency, also known as AAT deficiency or Alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein AAT. It is most common in the Caucasian population of northern Europe and North America. AAT deficiency is also the most common cause of genetic liver disease in children, and genetic emphysema (shortness of breath) in adults. Individuals suffering from AAT deficiency often develop severe obstructive pulmonary disease (COPD) causing disability and premature death. AAT deficiency is estimated to affect 200,000 people in North America and Europe.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology an
Page: 1 2 3 4 5 Related medicine technology :1
|SOURCE Talecris Biotherapeutics|
Copyright©2009 PR Newswire.
All rights reserved
. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD2
. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania3
. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention4
. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study5
. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.6
. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies7
. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund8
. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel9
. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting10
. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis11
. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy